Mylan intros generic Ortho Tri-Cyclen Lo

PITTSBURGH — Mylan on Tuesday announced the U.S. launch of its generic of contraceptive Ortho Tri-Cyclen Lo (norgestimate and ethinyl estradiol) tablets, following final approval from the Food and Drug Administration.

 

The drug had U.S. sales of about $488.6 million in the 12 months ending Sept. 30, 2015, according to IMS Health, and it is the 14th oral contraceptive Mylan has launched in the U.S.